Leap Therapeutics (LPTX)
LPTX
Oncology
BiotechSign Signal Grade
F
Signal Grade
7.8/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Clinical Activity
12
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
1
Clinical Trial
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
1 Phase 2
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Leap Therapeutics.
Full LPTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.